Given recent evidence that reduced Aβ clearance accounts for the majority of AD cases of sporadic nature [37], increasing microglial clearance through pan-PPAR modulation may offer a novel therapeutic strategy. The gene discussed is PPARA; the disease is Alzheimer disease.